Publication

Article

Supplements and Featured Publications

Newsletter - Inflammation, Metabolic Syndrome, and CV Risk Reduction
Volume10
Issue 2 Metab

Faculty Disclosure Statement

Dr Dunbar: Speakers' bureau: Kos, Pfizer; Dr Szapary: Grants/research support: Takeda; Speakers' bureau: Takeda, Pfizer; Dr Haffner: Reported no financial support; Dr Rader: Consultant/grants/research support: Abbott, AstraZeneca, Bristol-Myers Squibb, Fournier, Kos, Merck, Pfizer, Schering-Plough; Speakers' bureau: Abbott, AstraZeneca, Bristol-Myers Squibb, Kos, Merck, Pfizer, Schering-Plough.

This report includes discussion of insulin sensitizers, including metformin and the thiazolidinediones, for preventing type 2 0diabetes, an indication not currently approved by the FDA.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo